Company Overview and News

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to EPA:PHA / PHARMAGEST INTER. on message board site Silicon Investor.

Regeneron Pharmaceuticals Regeneron Pharmaceuticals Regeneron Pharmaceuticals ENPH - Enphase, worldu0027s leading solar microinverter player ENPH - Enphase, worldu0027s leading solar microinverter player ENPH - Enphase, worldu0027s leading solar microinverter player
INO - Inovio Pharmaceuticals - A NYSE Small-Cap INO - Inovio Pharmaceuticals - A NYSE Small-Cap INO - Inovio Pharmaceuticals - A NYSE Small-Cap Alphabet Inc. (Google) Alphabet Inc. (Google) Alphabet Inc. (Google)
Ionis Pharmaceuticals (IONS) Ionis Pharmaceuticals (IONS) Ionis Pharmaceuticals (IONS) GWPH GW Pharmaceuticals board GWPH GW Pharmaceuticals board GWPH GW Pharmaceuticals board
Madrigal Pharmaceuticals Madrigal Pharmaceuticals Madrigal Pharmaceuticals ACADIA Pharmaceuticals Inc (ACAD) ACADIA Pharmaceuticals Inc (ACAD) ACADIA Pharmaceuticals Inc (ACAD)
VPHM - Viropharma Inc VPHM - Viropharma Inc VPHM - Viropharma Inc Clinuvel Pharmaceuticals Ltd Clinuvel Pharmaceuticals Ltd Clinuvel Pharmaceuticals Ltd